This proposal for the continuation of a Specialized Program of Research Excellence (SPORE) in Breast Cancer at the John Hopkins Medical Institutions brings together a highly interactive and productive multidisciplinary program of translational research in breast cancer. The overall goal is reduction in breast cancer incidence, morbidity, and mortality via the focused pursuit of translational research. This renewal application will capitalize on its research momentum and strengths in molecular markers, prevention, and therapy through a portfolio of five integrated and translational research projects. Research Project 1 focuses on identification of molecular markers for progression of ductal carcinoma in situ, building on a successful research program for detecting epigenetic molecular markers. Projects 2, 3, and 4 pursue innovative approaches for breast cancer treatment that have been developed at Johns Hopkins -targeting epigenetic alterations to restore """"""""silenced"""""""" gene expression, use of fatty acid synthase inhibitors for breast cancer treatment, and application of combinatorial vaccine approaches to breast cancer. Project 5 explores the development of broccoli sprouts tea as a breast cancer prevention agent. Basic and clinical research investigators in these five research projects are supported by three established and effective core resources, Administration, Human Breast Tissue and Pathology, and Biostatistics. The SPORE also continues a highly productive Developmental Research Program for rapid seed funding of novel ideas at Hopkins and Howard Universities and an outstanding Career Development Program to facilitate career development of individuals with an interest in translational breast cancer research. In aggregate the SPORE will continue to promote translational research by maintaining a breast cancer research culture at Johns Hopkins that transcends academic departments, medical disciplines, and individual research skills and facilitates collaborative research efforts with other SPORE programs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Kuzmin, Igor A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Lo, Pang-Kuo (2018) FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends Diabetes Metab 1:
Cravero, Karen; Medford, Arielle; Pallavajjala, Aparna et al. (2018) Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Pract Lab Med 12:e00108
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Lo, Pang-Kuo (2017) The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open 1:
Haffner, Michael C; Esopi, David M; Chaux, Alcides et al. (2017) AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun 8:142
Sunay, Melek M E; Foote, Jeremy B; Leatherman, James M et al. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 46:112-123
Parsons, Heather A; Beaver, Julia A; Cimino-Mathews, Ashley et al. (2017) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:379-386
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc et al. (2016) Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7:6281-93
Lo, Pang-Kuo; Lee, Ji Shin; Liang, Xiaohui et al. (2016) The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. Cell Signal 28:1502-19

Showing the most recent 10 out of 282 publications